Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Purchased by Lester Murray Antman dba SimplyRich

Lester Murray Antman dba SimplyRich raised its stake in Janux Therapeutics, Inc. (NASDAQ:JANX) by 205.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 24,315 shares of the company’s stock after acquiring an additional 16,351 shares during the period. Lester Murray Antman dba SimplyRich’s holdings in Janux Therapeutics were worth $1,301,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in JANX. Charles Schwab Investment Management Inc. lifted its position in Janux Therapeutics by 202.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 234,191 shares of the company’s stock valued at $10,639,000 after purchasing an additional 156,675 shares during the last quarter. Algert Global LLC acquired a new stake in shares of Janux Therapeutics in the third quarter valued at approximately $1,112,000. Ally Bridge Group NY LLC bought a new stake in shares of Janux Therapeutics during the third quarter valued at approximately $4,943,000. FMR LLC raised its holdings in shares of Janux Therapeutics by 0.6% during the third quarter. FMR LLC now owns 7,824,675 shares of the company’s stock valued at $355,475,000 after buying an additional 47,075 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Janux Therapeutics by 6.2% during the third quarter. Geode Capital Management LLC now owns 662,594 shares of the company’s stock worth $30,107,000 after buying an additional 38,490 shares during the period. 75.39% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently commented on JANX. Stifel Nicolaus raised their target price on Janux Therapeutics from $70.00 to $115.00 and gave the company a “buy” rating in a research report on Tuesday, December 3rd. Lifesci Capital upgraded shares of Janux Therapeutics to a “strong-buy” rating in a research note on Friday, December 27th. Leerink Partners upped their price objective on shares of Janux Therapeutics from $79.00 to $91.00 and gave the stock an “outperform” rating in a report on Tuesday, December 3rd. HC Wainwright raised their target price on shares of Janux Therapeutics from $63.00 to $70.00 and gave the company a “buy” rating in a research note on Tuesday, December 3rd. Finally, Scotiabank upped their price target on shares of Janux Therapeutics from $42.00 to $62.00 and gave the stock a “sector perform” rating in a research note on Wednesday, December 4th. One research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $89.90.

Insider Activity

In other news, CEO David Alan Campbell sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $60.00, for a total transaction of $300,000.00. Following the sale, the chief executive officer now owns 293,054 shares in the company, valued at $17,583,240. The trade was a 1.68 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Andrew Hollman Meyer sold 3,334 shares of the company’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $42.29, for a total transaction of $140,994.86. Following the completion of the sale, the insider now owns 82,139 shares of the company’s stock, valued at approximately $3,473,658.31. This trade represents a 3.90 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 86,668 shares of company stock worth $4,872,515. Insiders own 29.40% of the company’s stock.

Janux Therapeutics Stock Performance

Shares of NASDAQ:JANX opened at $36.11 on Wednesday. The stock has a market capitalization of $1.90 billion, a price-to-earnings ratio of -30.86 and a beta of 3.16. Janux Therapeutics, Inc. has a 1-year low of $7.81 and a 1-year high of $71.71. The company has a 50 day moving average price of $50.54 and a 200 day moving average price of $48.23.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.